Skip to main content
Premium Trial:

Request an Annual Quote

DVS Sciences Raises $14.6M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DVS Sciences today announced it has raised $14.6 million in a Series A financing round, which will be used to build up the company's manufacturing capabilities for its multiplexed single cell analysis technology.

The platform called CyTOF-Maxpar comprises a high-throughput mass cytometer for individual cell analysis and the company's Maxpar reagents. The technology can simultaneous identify up to 100 biomarkers with "very high" resolution and a wide dynamic range, DVS said, and the platform eliminates spectral overlap issues and enables quantitative, highly multiplexed biomarker analysis.

Spun out of the University of Toronto last year, DVS has offices in Toronto and Sunnyvale, Calif.

Investors in the Series A round include 5AM Ventures, Pfizer Venture Investments, Mohr Davidow, the Roche Venture Fund, and the Ontario Institute for Cancer Research.

"This significant Series A financing puts us in a position to broadly commercialize our innovative instrumentation and reagents to help scientists accelerate biomedical research, enable personalized therapeutic diagnosis and prognosis, and transform drug discovery," Scott Tanner, CEO and Co-founder of DVS, said in a statement.

Andrew Schwab, venture partner at 5AM Ventures, added, "We believe that the CyTOF-Maxpar platform will transform the performance of cellular analysis. By enabling massively multiplexed experiments, researchers will be primed to better understand the cellular dynamics of disease states, stem cells, and other biologically relevant systems."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more